Principal at Analysis Group
Robert Vigil specialises in the application of economics and finance to complex commercial litigation matters. His work includes assessments of lost profits, reasonable royalties, price erosion and unjust enrichment in IP and breach of contract cases; evaluations of patented drug products’ commercial success in connection with generic manufacturers’ abbreviated new drug application submissions to obtain early market entry; and analyses of issues related to the granting of permanent injunctions, such as irreparable harm and causal nexus.
Dr Vigil has served as an expert witness on litigation matters in a variety of industries, including pharmaceuticals, medical devices, consumer products, telecommunications, computer hardware and software, and electronics. In non-litigation matters, he has assisted clients in valuing intellectual property for sale or licence; identifying and evaluating potential partners for licensing, acquisition or divestiture of assets; and analysing the impact of generic entry on prices and market shares of brand-name pharmaceutical products.
Dr Vigil is a frequent speaker on issues related to IP valuation and damages assessment, and has taught courses in microeconomics and econometrics at the University of Maryland.
He holds a PhD in economics (University of Maryland) and a BA in economics (Pepperdine University), and was granted the certified licensing professional designation by the Licensing Executives Society.